Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place June 8-10, 2022.

In his presentation, Dr. Belichard will provide an overview of the progress the Company has made with its advanced OncoMimics™ pipeline, including its first-in-class off-the-shelf therapeutic cancer vaccine, EO2401, as  well as its other fully owned EndoMimics™ pipeline for immune diseases using its Mimicry drug discovery platform.